Biotech Company CardiAI Opens Chest Pain Clinic in South Calgary
New Clinical Trial Studies Impact of COVID-19 on Heart Health:
Calgary, Alta (June 7, 2021) – Calgary-based biotech company CardiAI is launching a new clinical trial studying the long-lasting effects of COVID-19 on the pulmonary system at its new Chest Pain Clinic (250, 8500 Blackfoot Trail SE). The ACT study (Anti-Coronavirus Therapies) will evaluate if anti-inflammatory therapies prevent the progression of COVID-19 in both inpatients and outpatients. Researchers are now seeking high-risk individuals who are 18 or older, with a recent lab-confirmed case of COVID-19, to take part in the ACT study. Eligible participants can apply on the CardiAI website. The clinical trial will take place at the company’s newest facility specializing in chest pain services, in south Calgary.
“Our Chest Pain Clinic can help patients from all types of chest pains, especially after COVID-19” says Dr. Anmol Kapoor, CEO of CardiAI. “By studying the correlation between the two, our research and development team will be able to pinpoint the cause and create an advanced treatment for these patients that can help get their health back to what it was.”
CardiAI recognized a need for a clinic specializing in cardiac services after witnessing a surge of hospitalizations due to chest pain. The Chest Pain Clinic is determined to create a healthy community with industry-leading technology to provide the best healthcare. Patients need a referral to the clinic, which can be provided by their local doctor. Patients will be evaluated in a timely manner, so the right procedures and services can be recommended. The clinic provides a range of cardiac services including echocardiograms, electrocardiograms, pulmonary function tests, and more.
“We have a diverse healthcare team from Cardiologists, to internal medicine specialists, to nuclear medicine technicians, and more. With this team and our leading technology, our goal is to limit the need to go to hospitals and provide quality chest pain services to our patients in our clinic” Dr. Kapoor concludes.
According to the Public Health Agency of Canada, heart disease is the second leading cause of death in Canada. Approximately one in twelve (or 2.4 million people) adult Canadians over the age of twenty live with diagnosed heart disease. Men are two times more likely to suffer a heart attack than women, says the report. Almost 80% of premature heart disease and stroke can be prevented through healthy behaviours as stated by the Heart and Stroke Foundation.